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Ceftobiprole (BAL9141) is an investigational cephalosporin with broad in vitro activity against gram-
positive cocci, including enterococci. Ceftobiprole MICs were determined for 93 isolates of Enterococcus faecalis
(including 16 -lactamase [Bla] producers and 17 vancomycin-resistant isolates) by an agar dilution method
following the Clinical and Laboratory Standards Institute recommendations. Ceftobiprole MICs were also
determined with a high inoculum concentration (107 CFU/ml) for a subset of five Bla producers belonging to
different previously characterized clones by a broth dilution method. Time-kill and synergism studies (with
either streptomycin or gentamicin) were performed with two -lactamase-producing isolates (TX0630 and
TX5070) and two vancomycin-resistant isolates (TX2484 [VanB] and TX2784 [VanA]). The MICs of ceftobi-
prole for 50 and 90% of the isolates tested were 0.25 and 1 g/ml, respectively. All Bla producers and
vancomycin-resistant isolates were inhibited by concentrations of <1 and <4 g/ml, respectively, at the
standard inoculum concentration. Ceftobiprole MICs at a high inoculum concentration for a subset of five
Bla E. faecalis isolates were <1 g/ml. Bactericidal activity was observed against four isolates tested at
concentrations as low as 1 g/ml regardless of the production of -lactamase or vancomycin resistance. A
combination of ceftobiprole (0.5 g/ml) and streptomycin (25 g/ml) was synergistic against Bla TX0630 and
TX5070. Ceftobiprole (0.5 g/ml) plus gentamicin (10 g/ml) was synergistic against VanB isolate TX2484 and
showed enhanced killing, but not synergism, against TX2784 (VanA), despite the absence of high-level resis-
tance to gentamicin. In conclusion, ceftobiprole exhibited good in vitro activity against E. faecalis, including
Bla and vancomycin-resistant strains, and exhibited synergism with aminoglycosides against selected
isolates.
Enterococcal infections continue to be a challenge in clinical
practice due to the fact that these organisms have the ability to
quickly acquire and disseminate resistance genes. The intro-
duction of new agents into clinical practice (e.g., linezolid and
daptomycin, among others) has been shortly followed by de-
velopment of resistance (10). Furthermore, the treatment of
certain enterococcal infections (e.g., endocarditis) requires the
use of bactericidal (14) agents which decrease the choice of
antimicrobials even further.
Ceftobiprole (BPR) is a novel, broad-spectrum parenteral
cephalosporin with high affinities for gram-negative and gram-
positive penicillin-binding proteins (PBPs), including PBP 2a
from methicillin-resistant Staphylococcus aureus (MRSA) (2,
6) and PBP 2x from resistant pneumococci (5, 11). The in vitro
spectrum of activity includes both gram-positive and gram-
negative organisms, including S. aureus (both MRSA and MSSA
isolates) (2, 7), pneumococci (including penicillin- and ceftri-
axone-resistant isolates) (5), Streptococcus pyogenes and other
streptococci (11), Haemophilus influenzae and Moraxella ca-
tarrhalis (including -lactamase producers) (1), Escherichia
coli, Enterobacter cloacae, Klebsiella pneumoniae, Serratia marc-
escens, Citrobacter freundii, Pseudomonas aeruginosa, and Pro-
teus mirabilis lacking extended spectrum -lactamases (11, 19).
Against anaerobes, BPR had good in vitro activity against
Propionibacterium acnes, Peptostreptococcus anaerobius, Clos-
tridium innocuum, Finegoldia magna, Porphyromonas asaccha-
rolytica (including a -lactamase-producing isolate), and Por-
phyromonas somerae (9), although Bacteroides fragilis group
isolates have been found to be resistant (9, 23).
Against enterococci, BPR was reported to have in vitro
bactericidal activity against most strains of ampicillin- and van-
comycin-susceptible Enterococcus faecalis, with MICs for 50
and 90% of a small collection of E. faecalis isolates tested
(MIC50 and MIC90, respectively) of 0.5 and 4 g/ml (6, 11).
BPR exhibited bactericidal activity at concentrations of 4, 8,
and 16 g/ml against an ampicillin- and vancomycin-suscepti-
ble E. faecalis isolate (E. faecalis ATCC 29212) (6). Time-kill
studies failed to show synergism when BPR (8 g/ml) was
combined with gentamicin (at one-fourth of the MIC) against
two clinical isolates of E. faecalis (ampicillin and vancomycin
susceptible) (6). BPR had a MIC90 of 8 g/ml against ampi-
cillin-susceptible E. faecium (11), but it lacked activity against
ampicillin-resistant E. faecium (6, 11).
The objective of this work was to evaluate the in vitro activity
of BPR against a larger collection of E. faecalis isolates and use
time-kill curves and synergism studies (with aminoglycosides)
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to specifically assess BPR bactericidal activity against -lacta-
mase-producing (Bla) and vancomycin-resistant isolates.
MATERIALS AND METHODS
Bacterial strains. A total of 93 isolates of E. faecalis were included in this
study. They were isolated from five different countries (the United States, Chile,
Argentina, Lebanon, and Thailand), and the majority of the isolates were ob-
tained from patients’ clinical samples (mainly blood [from endocarditis and
nonendocarditis patients] and urine). The collection included 17 vancomycin-
resistant isolates and 15 -lactamase-producing E. faecalis. The Bla isolates had
previously been characterized by pulsed-field gel electrophoresis and multilocus
sequence typing (17), and confirmation of -lactamase activity was performed
with nitrocefin disks following the Clinical and Laboratory Standards Institute
recommendations (3). Isolates obtained from fecal samples of healthy volunteers
(two isolates) and animals and from animal feed (seven isolates) and laboratory
strains E. faecalis JH2-2 (12) and OG1RF (16) were also included in this study.
All isolates were kept at 80°C and recovered from frozen stocks.
MIC determinations. MICs of vancomycin, ampicillin, BPR (BAL9141), gen-
tamicin, and streptomycin were determined by an agar dilution method on
Mueller-Hinton agar II (Becton Dickinson & Company, Cockeysville, MD) as
recommended by the Clinical and Laboratory Standards Institute (3). BPR was
diluted in 9.9% glacial acetic acid and 1% high quality dimethyl sulfoxide as
recommended by the manufacturer (Johnson & Johnson, Raritan, NJ). Suscep-
tibilities of isolate TX5070 (a Bla transconjugant of E. faecalis JH2-7 [Table 1],
which is a thymine auxotroph and cannot grow on Mueller-Hinton broth) (12),
were performed on brain heart infusion (BHI) agar with a starting inoculum
concentration of 104 CFU/spot. For selected Bla E. faecalis isolates, BPR and
ampicillin MIC determinations were performed at a high inoculum concentra-
tion (107 CFU/ml) in Mueller-Hinton broth (Becton Dickinson & Company,
Cockeysville, MD). Control strains included E. faecalis ATCC 29212, S. aureus
ATCC 29213, and E. coli 25922.
Time-kill and synergism studies. The bactericidal activity of BPR was evalu-
ated by time-kill curves. Synergism studies were performed with a subinhibitory
concentration of either gentamicin (10 g/ml) or streptomycin (25 g/ml) (14).
The following E. faecalis isolates were chosen for time-kill and synergism studies
(Table 1): Bla strains E. faecalis TX0630, a clinical blood isolate originally
recovered in Argentina (4), and TX5070, a laboratory strain obtained in a mating
experiment with the first ever discovered Bla enterococcal isolate (E. faecalis
HH22, used as a donor) (15); E. faecalis JH2-7, a thymine auxotroph (12); and
vancomycin-resistant, ampicillin-susceptible isolates TX2484 and TX2784. Bac-
teria were grown in flasks in a final volume of 20 ml of BHI broth with a starting
inoculum concentration of 107 CFU/ml from an overnight culture. BPR was
added at concentrations of 1 and 2 g/ml for time-kill curve studies and 0.5 g/ml
for synergism studies, which are below the therapeutic levels achieved in humans
(22). The concentrations of aminoglycosides used in the synergy studies were
below the MICs for the organisms and produced no significant growth inhibition
in the absence of BPR. Concentrations of 10 g/ml gentamicin and 25 g/ml
streptomycin were found to yield the best killing activity. Viable counts were
determined at 0, 4, and 24 h by plating appropriate dilutions of the cultures on
BHI agar plates. Antibiotic carryover was eliminated by centrifuging 1-ml sam-
ples of the culture and resuspending the pelleted bacteria in 0.9% saline before
plating. Time-kill and synergism studies were performed two to four times per
strain. The level of detection was 10 CFU/ml, assuming maximum plating effi-
ciency. Bactericidal activity was defined as a 3-log10 decrease in the number of
CFU per milliliter between 0 and 24 h. Synergism was defined as a 2-log10
decrease in the number of CFU per milliliter between the combination of BPR
plus an aminoglycoside (gentamicin or streptomycin) and BPR alone at 24 h,
with a concentration of the aminoglycoside that did not affect the growth curve
of the test organism when used alone.
RESULTS
BPR MICs. The BPR MIC distribution of all isolates, in-
cluding the subgroups of vancomycin-resistant and Bla iso-
lates, is shown in Fig. 1. The BPR MIC90 and MIC50 for all
isolates were 1 and 0.25 g/ml, respectively, ranging from
0.015 to 4 g/ml. The presence of vancomycin resistance did
not influence BPR susceptibility; for 94% of the vancomycin-
resistant isolates, BPR MICs were 1 g/ml. Among the 16
-lactamase producers, the BPR MIC100 was 1 g/ml. Table 2
shows the BPR MICs for a subset of five -lactamase produc-
FIG. 1. Distribution of MICs of BPR (BAL9141) for clinical iso-
lates of E. faecalis, including vancomycin-resistant isolates. VanR, van-
comycin resistant.
TABLE 1. E. faecalis strains used in time-kill and synergism studies
Strain Relevant characteristic(s) Reference Bla
MIC (g/ml) HLR toaminoglycosides Synergisma
BPR AMPd VANe GENf STRg
TX0630 Blood isolate from Argentina recovered
in 1990
4 Yes 0.25 1 0.5 Yes No Yes
TX5070 JH2-7 transconjugant resulting from
mating with a bla strain (HH-22),
thymine auxotroph
12 Yes 0.125b 8b 8b Yes No Yes
TX2484 Houston blood isolate, 1994, VanB 4 No 0.5 0.5 256 No Yes Yes
TX2784 Human fecal isolate from Spain, 1998,
VanA
18 No 0.25 0.5 256 No Yes Noc
a With either 10 g/ml gentamicin or 25 g/ml streptomycin when appropriate.
b Determined with BHI agar since TX5070 does not grow on Mueller-Hinton agar. E. faecalis ATCC 29212 was used as a control.
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ers from different clonal origins at two inocula. The use of a
high inoculum concentration (107 CFU/ml) of these isolates
for MIC determination in broth resulted in an increase of two-
to eightfold in the MIC, but all MICs were2 g/ml (Table 2).
A similar increase occurred in isolates TX2484 and TX2784,
which lack the -lactamase enzyme (two- and fourfold in-
creases in the MIC at a high inoculum concentration).
Bactericidal activity of BPR. The bactericidal activity of
BPR was assessed by time-kill assays against four different
isolates of E. faecalis (Table 1). Figure 2 shows the in vitro
activity of BPR against two Bla strains (TX0630 in panel A
and TX5070 in panel B). Both isolates were highly resistant to
gentamicin but lacked high-level resistance (HLR) to strepto-
mycin (Table 1). Concentrations of BPR as low as 1 and 2
g/ml were bactericidal against both Bla strains, decreasing
the viable bacterial count (CFU per milliliter) ca. 4 log10 from
the starting inoculum concentration (time zero) (Fig. 2). Fig-
ure 3 shows that BPR was also bactericidal against vancomy-
cin-resistant isolates. For both TX2484 (a VanB isolate) and
TX2784 (a VanA isolate), BPR decreased the viable counts3
log10 CFU/ml at 24 h from the starting inoculum concen-
tration.
Synergism between BPR and aminoglycosides. Synergistic
aminoglycoside (either gentamicin or streptomycin) activity
was evaluated for two Bla and two vancomycin-resistant E.
faecalis isolates. For the Bla strains (which exhibit HLR to
gentamicin but not to streptomycin), addition of streptomycin
(25 g/ml) to BPR was synergistic (Fig. 2). The decrease in
viable counts (CFU) at 24 h was 2 log10 (ca. 3 log10 for
TX0630 and ca. 4 log10 for TX5070 compared with BPR alone)
(Fig. 2A and B). Similarly, the combination of BPR and gen-
tamicin (10 g/ml) was synergistic against vancomycin-resis-
tant isolate TX2484 (Fig. 3A) (reduction of ca. 2.5 log10
CFU/ml when gentamicin was added compared to BPR alone).
Addition of gentamicin (10 g/ml) decreased counts of isolate
TX2784 by less than 2 log10 CFU/ml at 24 h (Fig. 3B). The lack
of synergism in strain TX2784 was observed at BPR concen-
trations of 0.25 and 1 g/ml and gentamicin concentrations of
5 and 8 g/ml (data not shown).
DISCUSSION
BPR is a novel cephalosporin that has been shown to be
active against gram-positive organisms (including MRSA) and
also maintains the spectrum of extended-spectrum cephalospo-
rins against gram-negative bacteria (2, 11). The basis for BPR’s
potent activity against many organisms is its high affinity for
PBPs (including PBP 2a of MRSA) and stability against hy-
drolysis by -lactamases (11). Against enterococci, BPR dis-
plays properties unique among the cephalosporins, since it has
good activity against isolates of E. faecalis (6). A previous study
(11) showed that the MIC90 for a collection of 14 clinical
isolates of ampicillin-susceptible E. faecalis was 4 g/ml. The
results of our work support the potent in vitro activity of BPR
against E. faecalis from different geographical, clinical, and
host origins (MIC90 of 1 g/ml for our isolates). Furthermore,
our findings confirm that susceptibility to BPR in E. faecalis is
not affected by the presence of vancomycin resistance or by
-lactamase production in enterococci. Although a modest
inoculum concentration effect was seen with BPR for both
Bla and Bla isolates, the MIC remained 2 g/ml.
We also evaluated the bactericidal activity of BPR against
four strains of E. faecalis exhibiting either vancomycin resis-
tance (VanA and VanB phenotypes, Table 1) or ampicillin
FIG. 2. Time-kill and synergism studies of BPR and streptomycin against two Bla isolates of E. faecalis. Panel A, TX0630; panel B, TX5070.
Detection limit, 10 CFU/ml. Sm, streptomycin.
TABLE 2. BPR (BAL9141) MICs against different inocula of
Bla-producing E. faecalis from different clonal origins





High Standard GENd STRe
TX0921 BVEa (ST-7) 1 0.25 Yes Yes
TX0614 BVE (ST-6) 2 1 Yes Yes
TX0638 BVE (ST-7) 1 0.25 Yes Yes
TX0630 ACBb (ST-9) 1 0.125 Yes No
TX0645 Unrelated 1 0.25 Yes No
a BVE, Bla-producing and vancomycin-resistant endocarditis clone.
b ACB, Argentina-Connecticut Bla-producing clone.
c The standard inoculum concentration was 104 CFU/spot in agar, and the high
inoculum concentration was 107 CFU/ml in broth.
d GEN, gentamicin.
e STR, streptomycin.
VOL. 51, 2007 BPR-E. FAECALIS TIME-KILL AND SYNERGISM STUDY 2045
resistance due to the production of the -lactamase enzyme.
BPR was bactericidal in time-kill studies against all of the
strains at concentrations as low as 1 g/ml. Pharmacokinetic
studies (21, 22) have shown that single infusions of 750 mg of
BPR medocaril (a BAL9141 prodrug) led to mean plasma drug
concentrations above 4 g/ml for approximately 7 h (22) (the
MIC at which 100% of our E. faecalis isolates were inhibited,
including Bla isolates at a high inoculum concentration). Our
results support the fact that BPR would likely exhibit bacteri-
cidal activity against E. faecalis at the dose proposed. Our
findings are also in agreement with those of Deshpande et al.
(6), who showed that BPR (at concentration of 4, 8, and 16
g/ml) was bactericidal against E. faecalis ATCC 29212 and
two additional E. faecalis clinical isolates (tested at 8 g/ml).
Bactericidal activity against E. faecalis is a characteristic of
BPR that is unique among the cephalosporins and is likely to
be due to the high affinity for the enterococcal PBPs. BPR has
been shown to exhibit increased affinity for PBPs of several
gram-positive organisms (particularly PBP 2a of MRSA and S.
epidermidis) (11) compared with other -lactams. Moreover, it
has been shown that BPR acylates PBP 2a more rapidly than
other -lactam antibiotics and forms a more stable acyl-en-
zyme complex through a unique mode of interaction with the
protein (11).
Another important feature of BPR is its -lactamase stabil-
ity. The production of this enzyme is rare among clinical iso-
lates of E. faecalis, but its presence compromises the use of the
most effective antienterococcal -lactams (e.g., ampicillin).
The enterococcal -lactamase is identical to the staphylococcal
class A enzyme encoded by the blaZ gene (15), and BPR is a
poor substrate for these enzymes, which explains its excellent
activity against -lactamase-producing E. faecalis.
The combination of -lactams and aminoglycosides has been
widely used in the treatment of enterococcal infections that
require bactericidal therapy for optimal cure rates (e.g., endo-
carditis) (14). Previously, no synergistic activity was observed
for two strains of E. faecalis when using concentrations of BPR
of 8 g/ml and gentamicin at one-fourth of the MIC for the
strains (6). In contrast with these data, we were able to dem-
onstrate synergism in three out of four isolates of E. faecalis
when using a BPR concentration of 0.5 g/ml (which is equal
to or slightly higher than the MIC). An explanation for this
discrepancy is that, at concentrations as high as 8 g/ml (as
used by Deshpande et al. [6]), the killing effect of BPR is so
marked that it may mask the effect of the aminoglycoside.
Consistent with this hypothesis is the fact that we were unable
to show any synergism when using BPR concentrations of 1, 2,
and 4 g/ml (data not shown).
Synergistic activity was evident in the presence of -lacta-
mase in different host backgrounds. BPR combined with strep-
tomycin at a concentration of 25 g/ml each exhibited syner-
gism against both TX0630 (a Bla clinical strain) and TX5070
(a Bla laboratory strain). Both isolates have HLR to genta-
micin but not to streptomycin. Similarly, the combination of
BPR (0.5 g/ml) and gentamicin (10 g/ml) was synergistic
against one vancomycin-resistant (VanB) isolate of E. faecalis.
However, although a decrease in viable counts caused by the
combination of BPR and gentamicin compared to BPR alone
was observed at 24 h in isolate TX2484 (a VanA human fecal
isolate from Spain), the reduction in the number of CFU per
milliliter did not reach the cutoff for synergism (1 log10 but
2 log10). These results indicate that, with selected isolates of
Bla or vancomycin-resistant E. faecalis, a combination of
BPR and an aminoglycoside could be potentially useful in
clinical settings where bactericidal therapy is important. In vivo
studies are of paramount importance to clarify this issue.
As opposed to E. faecalis isolates, E. faecium isolates have
developed different strategies for -lactam resistance which
include hyperproduction of PBP 5, which has a low affinity for
-lactams and is capable of substituting for the functions of
-lactam-susceptible PBPs (8), and by introducing amino acid
substitutions into the penicillin-binding domain of PBP 5 (13,
20, 24). Previous studies (6) have shown that BPR had no
activity against ampicillin-resistant E. faecium, indicating that
it is likely that the affinity of BPR for PBP 5 of E. faecium is low
and therefore not clinically useful for the treatment of ampi-
cillin-resistant E. faecium infections.
In conclusion, we demonstrated that BPR has potent in vitro
activity against the largest collection of E. faecalis isolates
tested to date. The activity was not affected by vancomycin
resistance or production of -lactamase, and synergism with
aminoglycosides can be achieved for selected strains. There-
fore, BPR emerges as a promising agent with potential for
FIG. 3. Time-kill and synergism studies of BPR and gentamicin against two vancomycin-resistant isolates of E. faecalis. Panel A, TX2484
(VanB); panel B, TX2784 (VanA). Detection limit, 10 CFU/ml. GEN, gentamicin.
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future use to treat Bla and vancomycin-resistant E. faecalis
infections.
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